Baxdrostat versus osilodrostat: steroid biosynthesis in human adrenocortical cells
Endocrine Connections · 01.07.2026 · 15 (7)
DOI: 10.1530/ec-25-0807 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Connections, online erschienen am 17.06.2026. Verfasst von Yuki Taki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Diagnosis, Chiba University Graduate School of Medicine , Chiba, Japan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
To compare the functional selectivity of baxdrostat versus osilodrostat in primary human adrenocortical cells, focusing on aldosterone suppression while preserving cortisol biosynthesis, we conducted an experimental ex vivo study using primary cells derived from aldosterone-producing adenomas, cortisol-producing tumors, and normal adrenal cortex. Cells were stimulated with the adrenocorticotropic hormone (10 nM) and exposed for 72 h to baxdrostat, osilodrostat, or metyrapone (0–10 μM). Outcomes included geometric mean (GM) IC50 values for aldosterone and cortisol, LC–MS/MS steroid profiling, and molecular docking to CYP11B2/CYP11B1. In aldosterone-producing adenoma cells, baxdrostat selectively inhibited aldosterone (GM IC50 = 0.041 μM) and did not achieve 50% cortisol suppression in cortisol-producing tumor or normal adrenal cortex within 0–10 μM. Osilodrostat inhibited aldosterone (GM IC50 = 0.0022 μM) and cortisol (GM IC50 = 0.196 μM). Steroid profiling showed a modest, selective rise in 11-deoxycorticosterone with baxdrostat (+3.76-fold), whereas osilodrostat produced larger increases in 11-deoxycorticosterone (+25.4-fold) together with androgen elevations. Docking supported the mechanism: baxdrostat showed stronger predicted binding to CYP11B2 (−11.5 kcal/mol) than osilodrostat (−8.7 kcal/mol) with limited engagement of CYP11B1. Baxdrostat demonstrated greater functional selectivity for CYP11B2, with minimal cortisol axis impact and smaller upstream precursor accumulation than osilodrostat. These human-tissue data inform dose selection and safety monitoring strategies for selective aldosterone synthase inhibition in aldosterone-mediated and treatment-resistant hypertension.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Diagnosis, Chiba University Graduate School of Medicine , Chiba, Japan.
- Research Institute of Disaster Medicine, Chiba University , Chiba, Japan.
- Department of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University , Chiba, Japan.
- Department of Medical Physiology, Graduate School of Medicine, Chiba University , Chiba, Japan.
- Department of Pathology, Tohoku University School of Medicine , Sendai, Japan.
- Division of Pathology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University , Sendai, Japan.
ORCID-Profile: Tomoaki Tanaka
Zitieren
APA
Taki, Y., Kono, T., Sakuma, I., Hashimoto, N., Yokoyama, M., Kawakami, E., Miki, T., Sasano, H., Nakamura, Y., & Tanaka, T. (2026). Baxdrostat versus osilodrostat: steroid biosynthesis in human adrenocortical cells. Endocrine Connections, 15(7). https://doi.org/10.1530/ec-25-0807
Vancouver
Taki Y, Kono T, Sakuma I, Hashimoto N, Yokoyama M, Kawakami E, et al. Baxdrostat versus osilodrostat: steroid biosynthesis in human adrenocortical cells. Endocrine Connections. 2026;15(7). doi:10.1530/ec-25-0807
BibTeX
@article{Taki2026,
author = {Taki, Yuki and Kono, Takashi and Sakuma, Ikki and Hashimoto, Naoko and Yokoyama, Masataka and Kawakami, Eiryo and Miki, Takashi and Sasano, Hironobu and Nakamura, Yasuhiro and Tanaka, Tomoaki},
title = {Baxdrostat versus osilodrostat: steroid biosynthesis in human adrenocortical cells},
journal = {Endocrine Connections},
year = {2026},
volume = {15},
number = {7},
doi = {10.1530/ec-25-0807}
}
EUVIMED